International Journal of Life Science and Pharma Research
https://ijlpr.com/index.php/journal
<p data-start="131" data-end="696"><strong>Welcome to the IJLPR</strong></p> <p data-start="131" data-end="696">International Journal of Life Science and Pharma Research (IJLPR) [Online ISSN: 2250-0480] is a peer-reviewed international journal, published quarterly in English. IJLPR aims to disseminate high-quality review and research articles in the rapidly evolving fields of pharmaceutical and life sciences. As an open-access online journal, it ensures unrestricted access to all published content. Manuscripts submitted to the journal undergo an initial assessment by the editorial team and are subsequently reviewed by qualified peer reviewers, with additional expert evaluation as needed.</p> <p data-start="131" data-end="696"> </p>Lapin Press Publications [LPP]en-USInternational Journal of Life Science and Pharma Research2250-0480A Comparative Review Analysis of Diabetic Foot Ulcers in the India and United States
https://ijlpr.com/index.php/journal/article/view/2053
<p>Diabetic foot ulcers (DFUs) are one of the most serious consequences of diabetes mellitus, contributing significantly to infection, hospitalization, lower-limb amputation, decreased quality of life, and healthcare expenses. The burden of DFUs in India and the US between 2020 and 2025 is compared in this review, with an emphasis on prevalence, incidence, risk factors, clinical features, sequelae, and economic effects. The prevalence of DFUs is estimated to be around 6.3% worldwide, with the United States reporting a greater frequency (around 13%) than the pooled estimate for India (6.2%). India's vast population of diabetics results in a significant absolute burden, with significant regional and healthcare setting variations, notwithstanding the country's reported lower frequency. While neuro-ischemic ulcers are more commonly described in Western populations, DFUs in India are primarily neuropathic. Longer duration of diabetes, peripheral neuropathy, peripheral vascular disease, advanced age, male sex, infection, and poor foot care are important risk factors. In both countries, DFUs often lead to amputation, delayed recovery, recurrence, and substantial financial burden. However, direct comparisons are limited by variations in demographic characteristics, study methodologies, diagnostic techniques, and healthcare availability. Early screening, patient education, appropriate foot care, pressure offloading, infection control, vascular evaluation, and multidisciplinary care are all necessary for effective prevention.To produce accurate estimates and improve DFU prevention and clinical outcomes in India and the US, community-based surveillance must be strengthened and prospective studies must be carried out.</p>Pranathi KurapatiDevi Vara Prasad RajulapatiTabitha R J Chandrika P
Copyright (c) 2026
https://creativecommons.org/licenses/by-nc-nd/4.0
2026-10-012026-10-0181910.22376/ijlpr.v16i3.2053Marine-Derived Inhibitors of MMP-2 and MMP-9: Emerging Therapeutic Strategies Against Cancer
https://ijlpr.com/index.php/journal/article/view/2050
<p>Cancer metastasis remains the principal cause of cancer-related mortality and represents one of the greatest challenges in effective cancer therapy. A critical event in the metastatic cascade is the dysregulated expression and activity of matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, which degrade extracellular matrix components and facilitate tumor cell invasion, migration, and dissemination. These gelatinases interact with multiple signaling pathways and regulatory molecules, thereby promoting the invasion of cancer cells from the primary tumor into surrounding tissues and distant organs, ultimately leading to the formation of secondary tumors. Consequently, selective inhibition of MMP-2 and MMP-9 has emerged as a promising therapeutic strategy for preventing cancer progression and metastasis. In recent years, natural products derived from medicinal plants, their bioactive phytochemicals, and marine organisms have attracted considerable attention due to their ability to modulate MMP activity with improved target specificity and reduced toxicity. These natural compounds can suppress MMP-2 and MMP-9 expression or activity, thereby inhibiting cancer cell migration, invasion, angiogenesis, and metastatic spread while promoting apoptosis, sparing normal cells. This review summarizes the current understanding of the biological roles of MMP-2 and MMP-9 in carcinogenesis and metastasis. It also critically evaluates the therapeutic potential of marine-derived natural products as inhibitors of these metalloproteinases. A comprehensive understanding of the molecular mechanisms underlying MMP-2 and MMP-9 regulation and their modulation by natural compounds may facilitate the development of novel, effective, and safer anti-metastatic therapies for cancer management.</p>Avinaba Mukherjee
Copyright (c) 2026 Avinaba Mukherjee
https://creativecommons.org/licenses/by-nc-nd/4.0
2026-11-022026-11-02Integrated Biomarker Response ranks the systemic oxidative burden of modified nucleoside analogues and quantifies quercetin-mediated redox recovery in LPS-induced endotoxemia in rats
https://ijlpr.com/index.php/journal/article/view/2052
<p>Modified nucleoside analogues are re-emerging as candidate antibacterial scaffolds, but their systemic redox cost under inflammation and the value of a dietary antioxidant co-treatment are poorly quantified. Eighty-five male Wistar rats were randomised into 17 groups (n = 5): naive control, LPS-only, LPS + quercetin, and seven analogues (2FaraA, 6ClAraPur, araCMP, TTU, FluMP, araC, cCMP) each with and without quercetin on a uniform LPS background. Six hepatic oxidative markers and eleven haematological markers were measured and compressed using the Integrated Biomarker Response (IBR), an Oxidative Stress Index (OSI), principal-component analysis (PCA) and ROC analysis. The analogues imposed a reproducible, rank-ordered oxidative burden: araC (IBR = 21.57) >cCMP (18.57) > 2FaraA (16.34) >FluMP (13.38) > TTU (12.74) > 6ClAraPur (11.43) >araCMP (11.30), all above LPS-only (7.70) and control (0.40). OSI mirrored IBR (Pearson r = 0.983). Quercetin restored the IBR toward control in every analogue, by 64.9–84.3 % (mean 74.4 %), with the largest rescue for araC, the most pro-oxidant member. PC<sub>1</sub> captured 80.2 % of variance, ordering the groups along a single oxidative-burden axis. The antioxidant enzymes GPX, GSH and SOD (directed AUC 0.81–0.86) were most sensitive to quercetin, whereas serum AST was not (Kruskal–Wallis p = 0.73), indicating a redox-specific rather than a generalised hepatoprotective effect. These results establish a compact, integrative safety-screening framework that ranks modified nucleosides by systemic oxidative liability and demonstrates a consistent, class-independent quercetin redox rescue of approximately 74 %, offering a quantitative read-out for nucleoside-based antibacterial development.</p>ArshedAbd Ali ShihadAliaksei G Sysa
Copyright (c) 2026
https://creativecommons.org/licenses/by-nc-nd/4.0
2026-09-302026-09-301710.22376/ijlpr.v16i3.2052Statistical Development of Posaconazole Smedds via D-Optimal Mixture Design under a QBD Paradigm
https://ijlpr.com/index.php/journal/article/view/2038
<p><strong>Introduction:</strong> Posaconazole is a class II BCS (Biopharmaceutical Classification System) antifungal drug. Current study objective is to enhance solubility by formulating SMEDDS guided by QbD via experimental design. <strong>Methods:</strong> Solubility studies in surfactants, oils, and co-surfactants were conducted. Critical quality attributes (CQA), emulsification time (R1) and drug release (R2) were taken as dependent factors. Formulations were prepared as per d-optimal mixture design and evaluated for physico-chemical parameters and dissolution studies. <strong>Results:</strong> Maximum solubility 6.953mg/ml in Tween 40, 1.630mg/ml in Transcutol & 0.187mg/ml in Capmul MCM were selected as surfactant, co-surfactant and oil phases. Excipient compatibility was confirmed by FTIR studies. Soluplus was used as Precipitation Inhibitor. Independent factors and dependent factors were mathematically co-related by Linear model and cubic model. From Overlay plots OF1 formulation (43.30ml Capmul MCM, 20ml Tween 40, 36.69ml Transcutol) with desirability co-efficient 0.991 was optimised. This formulation Globule size is 62.7nm, PDI 0.08 and Zeta-potential -0.19 mV. <strong>Discussion:</strong> Quality target product profile was postulated and CQA assessed by experimental design. Oil, Capmul MCM influenced rate of emulsification positively but decreased drug release. Surfactant and co-surfactant increased drug release but slowed emulsification time. D-Optimal mixture design was validated by correlation co-efficient of approx. 0.9 between predicted and actual responses. Formulations followed Fickian diffusion mechanism and were stable for one month at 40°C/75% RH. <strong>Conclusion:</strong> Posaconazole solubility as SMEDDS has been enhanced.</p>Pooja JupallyUsharani SagarlaVasavi DevireddyJaya Lakshmi MalladiNaseeb Basha ShaikPrasanthi domaraju
Copyright (c) 2026 Jupally Pooja, Sagarla Usharani, Vasavi Devireddy, Malladi Jaya Lakshmi, Shaik Naseeb Basha, Prasanthi Domaraju
https://creativecommons.org/licenses/by-nc-nd/4.0
2026-11-022026-11-0210.22376/ijlpr.v16i3.2038Prediction of Outcome by Measuring Serum Lactate Concentration-Time Data in Patient with Acute Paraquat Poisoning
https://ijlpr.com/index.php/journal/article/view/2055
<p>The standard prognostic assay for acute paraquat poisoning—plasma paraquat concentration—is frequently unavailable in resource-limited settings. While serum lactate and time-lagged composite models have been proposed as accessible alternatives, they lack robust external validation. To externally validate an established arterial lactate-time prognostic model using venous serum lactate, and evaluate its utility for predicting in-hospital mortality. <em>Methods: </em>We conducted a hospital-based observational study of 46 adults presenting with acute paraquat poisoning at a single center in Central India. Model discrimination was assessed using the Area Under the Receiver Operating Characteristic Curve (AUC) with bootstrap 95% confidence intervals (CIs). The cohort experienced a 78.26% in-hospital mortality rate. Admission serum lactate alone demonstrated excellent discrimination (AUC 0.963; 95% CI: 0.896–1.000). The externally validated lactate-time model yielded a lower point estimate (AUC 0.861; 95% CI: 0.718–0.966). An in-sample optimal serum lactate cut-off of 3.0 mmol/L predicted mortality with a sensitivity of 0.944. Time lag did not independently predict mortality in an exploratory multivariable model (<em>p </em>= 0<em>.</em>153). In this setting, complex composite models did not demonstrate a statistically significant discriminative advantage over unadjusted serum lactate. While a 3.0 mmol/L triage threshold shows promise, its in-sample derivation requires future multicenter validation.</p>Rajat Kumar PandeyRajeev Lochan KharePrachi DubeyP. Lakra D
Copyright (c) 2026
https://creativecommons.org/licenses/by-nc-nd/4.0
2026-10-302026-10-30465110.22376/ijlpr.v16i3.2055Screening, Characterization and Evaluation of a Potent Keratinolytic Bacteria for Biodegradation of Poultry Feather Waste In and Around Vijayawada
https://ijlpr.com/index.php/journal/article/view/2056
<p>Keratinases are proteolytic enzymes capable of degrading keratinous proteins, which are highly resistant and insoluble structural proteins abundantly present in feathers, hair, wool, nails, and other biological materials. Unlike conventional proteases, keratinases possess the ability to attack the complex structure of keratin; however, most keratinases reported to date are unable to completely solubilize native keratin. The unique mechanism of keratin degradation therefore remains an intriguing and incompletely understood phenomenon in the field of proteolytic enzymes. Keratinases have gained considerable attention due to their wide range of potential applications in feed, detergent formulations, leather processing, pharmaceutical industries, waste management, and other biotechnological processes. Poultry feather waste is produced in large quantities by the poultry industry and represents a significant environmental concern because of its high keratin content, resistance to degradation, and accumulation in the environment. Microbial degradation of feather waste using keratinolytic microorganisms offers an eco-friendly and sustainable alternative to conventional disposal methods and may facilitate the conversion of feather waste into valuable products. The present investigation focuses on the isolation and characterization of keratinolytic bacteria capable of producing extracellular keratinase and their potential for keratin degradation. Soil samples collected from areas surrounding poultry farms in and around Vijayawada were screened for keratinase-producing bacteria. The selected isolates were evaluated for keratinase production and feather degradation efficiency, followed by biochemical and molecular characterization for identification. The study aims to identify efficient extracellular keratinase-producing bacterial strains with potential applications in sustainable poultry feather waste management and biotechnological processes.</p>Saritha NMeghala CH
Copyright (c) 2026
https://creativecommons.org/licenses/by-nc-nd/4.0
2026-10-302026-10-30202810.22376/ijlpr.v16i3.2056Fetomaternal Outcome of Thrombocytopenia in Pregnancy
https://ijlpr.com/index.php/journal/article/view/2057
<p>Pregnancy is associated with substantial physiological adaptation of the maternal haematological system, and even minor deviations in platelet count can affect both maternal and fetal well-being. Thrombocytopenia, defined as a platelet count below 150,000/µL, is the second most common haematological abnormality in pregnancy after anaemia, with reported prevalence ranging from 6.6% to 11.6%. While gestational thrombocytopenia is the most frequent and benign cause, other aetiologies such as immune thrombocytopenic purpura, preeclampsia, HELLP syndrome, acute fatty liver of pregnancy and infections can indicate serious systemic disease and adversely affect outcomes. This prospective case-control study was undertaken to identify the aetiological factors responsible for thrombocytopenia in pregnancy and to evaluate its maternal and fetal outcomes. The study was conducted in the Department of Obstetrics and Gynaecology, B. J. Medical College and Civil Hospital, Ahmedabad, over a period of two years (October 2023-October 2025). One hundred antenatal women were enrolled, comprising 50 women with thrombocytopenia (platelet count <150,000/µL) as cases and 50 women with normal platelet counts as controls, and were followed prospectively till delivery. Gestational thrombocytopenia was the commonest cause (52%), followed by immune thrombocytopenic purpura (20%), viral infections (12%), preeclampsia (8%), HELLP syndrome (6%) and acute fatty liver of pregnancy (2%). Moderate thrombocytopenia was the most frequent severity category (50%). Women with thrombocytopenia had a significantly earlier mean gestational age at delivery, a higher requirement for blood product transfusion, and a higher rate of pancytopenia compared with controls. Fetal and neonatal outcomes, including low birth weight, preterm birth, intrauterine growth restriction, NICU admission, intrauterine death and perinatal mortality, were all significantly worse among women with thrombocytopenia. Maternal complications such as abruption, postpartum haemorrhage and disseminated intravascular coagulation were more frequent among cases, although the difference did not reach statistical significance. This study confirms that thrombocytopenia in pregnancy, though frequently due to a benign gestational cause, is associated with a significantly increased risk of adverse maternal and, more prominently, fetal outcomes, underscoring the need for early aetiological diagnosis, close antenatal surveillance and multidisciplinary management to optimise outcomes for both mother and baby.</p>Yogita KambaliyaSugandha PatelVishva Sangani
Copyright (c) 2026
https://creativecommons.org/licenses/by-nc-nd/4.0
2026-11-022026-11-02404510.22376/ijlpr.v16i3.2057Regulatory Pathways for Generic Antiviral Drugs: ANDA Requirements in the USA Compared With BRICS
https://ijlpr.com/index.php/journal/article/view/2059
<p>Generic antiviral medicines widened access to treatment for chronic and epidemic viral infections once patents on branded products expired. Approval requirements for generic medicines differed between countries, and earlier comparisons either described frameworks that were later replaced or gave little attention to antiviral-specific bioequivalence expectations. This study compares the abbreviated new drug application pathway of the United States Food and Drug Administration with generic drug registration in Brazil, Russia, India, China and South Africa, and it illustrates product-specific bioequivalence expectations for two antivirals, acyclovir topical cream and oseltamivir phosphate capsules. The novelty of the study lies in combining country-level procedures with antiviral case studies and in correcting superseded descriptions found in earlier compilations. The work is a descriptive comparative review. Regulatory instruments, regulator publications, product-specific guidances and published comparative studies are compiled, and six parameters (regulator, legal basis, dossier format and language, review structure, bioequivalence approach and indicative review duration) are tabulated for each country. Time-sensitive items are checked against notices current in November 2026. No statistical analysis is applicable to this descriptive study. All six jurisdictions use a dossier organised on the Common Technical Document and require proof of bioequivalence to a reference product, but they differ in legal basis, language, review structure, reliance on assessments by other regulators, patent-linkage mechanisms and reported review duration. Earlier descriptions are superseded in several respects: the Chinese and South African regulators have been renamed, Russia registers medicines under Eurasian Economic Union rules, the Brazilian generic requirements are consolidated in a 2022 resolution, and the Indian rules of 2019 replaced Schedule Y. The acyclovir case shows that a topical product can be approved through formulation sameness with in vitro release testing or through a clinical endpoint study, whereas the oseltamivir case shows that an oral capsule can be approved through a biowaiver based on the Biopharmaceutics Classification System or through fasting and fed crossover studies. Convergence on the Common Technical Document and on bioequivalence principles lowers the barrier to multi-country filing, but national legal instruments, language, timelines and product-specific expectations still require a jurisdiction-specific strategy.</p>Shirisha MangilipallyDeepthi LingalaJayasri DusaApoorva Teja SNikitha BogiReshma AelukaPrasanthi D
Copyright (c) 2026
https://creativecommons.org/licenses/by-nc-nd/4.0
2026-11-132026-11-13647510.22376/ijlpr.v16i3.2059